DnB Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.72M Buy
26,071
+8,516
+49% +$663K ﹤0.01% 591
2026
Q2
$1.31M Buy
17,555
+714
+4% +$50K ﹤0.01% 627
2026
Q1
$1.25M Buy
16,841
+2,390
+17% +$173K ﹤0.01% 624
2025
Q4
$1.11M Buy
14,451
+4,028
+39% +$264K ﹤0.01% 630
2025
Q3
$541K Buy
+10,423
New +$508K ﹤0.01% 670

Other funds holding BBIO

DnB Asset Management's BBIO Position: Q3 2026 in Review

DnB Asset Management increased its BridgeBio Pharma (BBIO) stake by 49% in Q3 2026, buying an estimated $663K and bringing the position to 26,071 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #591.

DnB Asset Management first reported a position in BBIO in Q3 2025 and has held it in 5 quarters since. 348 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • DnB Asset Management held 26,071 shares of BridgeBio Pharma worth $1.72M as of Q3 2026.
  • DnB Asset Management bought 8,516 BridgeBio Pharma shares in Q3 2026, an estimated $663K.
  • BridgeBio Pharma made up ﹤0.01% of DnB Asset Management's portfolio in Q3 2026, its #591 holding.
  • DnB Asset Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 5 quarters since.
  • 348 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on DnB Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.